IL33 Specific Neutra™ Antibody Products
Product listInterleukin 33 (IL33) is a cytokine belonging to the IL-1 family, primarily expressed in structural and immune cells, including epithelial and endothelial cells, fibroblasts, and immune cells like mast cells, dendritic cells, and macrophages. Structurally, IL33 contains a chromatin-binding motif in its N-terminus and is released upon cellular damage or stress. It functions as an alarmin, alerting the immune system to tissue injury or infection. IL33 binds to its receptor, ST2, activating various immune cells and promoting inflammatory responses. Additionally, it also plays a vital part in tissue healing, allergic reactions, and autoimmune diseases.
Its Gene ID: 90865, UniProtKB ID: O95760, and OMIM ID: 608678.
IL33 Signaling Pathway
IL33 signaling begins with its binding to the heterodimeric receptor complex composed of ST2 (also referred to as IL1RL1) and IL-1 receptor accessory protein (IL-1RAP). Upon ligand-receptor interaction, a conformational change occurs, leading to the recruitment of the MyD88 adaptor protein. This initiates downstream signaling cascades, including NF-κB, MAPK, and IRF pathways. Activation of these pathways promotes increased production of pro-inflammatory cytokines such as IL-8, IL-6, TNF-α, and type 2 cytokines like IL-4, IL-5, and IL-13. IL33 signaling also promotes the recruitment and activation of various immune cells, including mast cells, eosinophils, Th2 cells, and regulatory T cells.
Fig.1 IL33/ST2 signaling pathway.1
IL33 in Inflammation and Diseases
IL33 is implicated in various inflammatory diseases, including asthma, allergic rhinitis, atopic dermatitis, and inflammatory bowel disease, where it exacerbates inflammation through the activation of immune cells and the production of pro-inflammatory cytokines. Additionally, IL33 has been linked to other diseases such as cardiovascular disorders, where it contributes to vascular inflammation and atherosclerosis progression. Furthermore, IL33 dysregulation is linked to neuroinflammatory diseases such as Alzheimer's and multiple sclerosis. Targeting IL33 signaling pathways represents a promising therapeutic approach for modulating inflammation and treating associated diseases.
Antibodies Targeting IL33
Therapeutic antibodies targeting IL33 aim to neutralize its activity and mitigate inflammatory responses in various diseases. These antibodies typically bind to IL33, preventing its interaction with its receptors. By blocking IL33 signaling, these antibodies inhibit downstream inflammatory pathways, lowering pro-inflammatory cytokine production and dampening immune cell activation. Research has shown promising results in preclinical models and early clinical trials across a spectrum of IL33-related inflammatory diseases, including asthma, allergic rhinitis, and inflammatory bowel disease. The mechanism of action involves attenuation of inflammation and restoration of tissue homeostasis, highlighting the therapeutic potential of IL33-neutralizing antibodies in managing chronic inflammatory conditions. Additionally, an antibody targeting IL33 showed efficacy in clinical trials for improving lung function in patients with chronic obstructive pulmonary disease (COPD).
Fig.2 A schematic of the proposed mode of action of an anti-IL33 antibody.2
Creative Biolabs offers more than one hundred kinds of different anti-IL33 antibody products to meet your various research needs. These antibodies are recombinantly expressed and could be used in eight applications.
REFERENCES
- Griesenauer, Brad, and Sophie Paczesny. "The ST2/IL-33 axis in immune cells during inflammatory diseases." Frontiers in immunology 8 (2017): 244258. Distributed under Open Access license CC BY 4.0, without modification.
- England, Elizabeth, et al. "Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction." Scientific Reports 13.1 (2023): 9825. Distributed under Open Access license CC BY 4.0. The image was modified by extracting and using only part of the original image.
